Abstract
Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play critical roles in embryonic patterning, neuronal targeting, and vascular development during embryogenesis. In adults, Eph RTKs and their ligands, the ephrins, are frequently overexpressed in a variety of cancers and tumor cell lines, including breast, prostate, non-small cell lung and colon cancers, melanomas, and neuroblastomas. Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interaction both in tumor cells and in tumor microenvironment, namely the tumor stroma and tumor vasculature. As such, Eph RTKs represent attractive potential targets for drug design, as targeting these molecules could attack several aspects of tumor progression simultaneously. This review will focus on recent advances in dissecting the role of Eph RTKs in tumor cells, tumor angiogenesis, and possible contribution to trafficking of inflammatory cells in cancer.
Keywords: eph receptors, receptor tyrosine kinases, ligands, signaling, cancer cells, tumor cells, tumor microenvironment, tumor anglogenesis
Current Pharmaceutical Design
Title: Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Volume: 10 Issue: 27
Author(s): Dana Brantley-Sieders, Sonja Schmidt, Monica Parker and Jin Chen
Affiliation:
Keywords: eph receptors, receptor tyrosine kinases, ligands, signaling, cancer cells, tumor cells, tumor microenvironment, tumor anglogenesis
Abstract: Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play critical roles in embryonic patterning, neuronal targeting, and vascular development during embryogenesis. In adults, Eph RTKs and their ligands, the ephrins, are frequently overexpressed in a variety of cancers and tumor cell lines, including breast, prostate, non-small cell lung and colon cancers, melanomas, and neuroblastomas. Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interaction both in tumor cells and in tumor microenvironment, namely the tumor stroma and tumor vasculature. As such, Eph RTKs represent attractive potential targets for drug design, as targeting these molecules could attack several aspects of tumor progression simultaneously. This review will focus on recent advances in dissecting the role of Eph RTKs in tumor cells, tumor angiogenesis, and possible contribution to trafficking of inflammatory cells in cancer.
Export Options
About this article
Cite this article as:
Brantley-Sieders Dana, Schmidt Sonja, Parker Monica and Chen Jin, Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment, Current Pharmaceutical Design 2004; 10 (27) . https://dx.doi.org/10.2174/1381612043383160
DOI https://dx.doi.org/10.2174/1381612043383160 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry The Current Chemical Utility of Marine and Terrestrial Filamentous Fungi in Side-Chain Chemistry
Current Organic Chemistry Tumor Promoters - Microcystin-LR, Nodularin and TNF-α and Human Cancer Development
Anti-Cancer Agents in Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents TP73, An Under-Appreciated Player in Non-Hodgkin Lymphoma Pathogenesis and Management
Current Molecular Medicine Radiotracers in Oncology
Current Radiopharmaceuticals Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry In Silico Approach to Finding New Active Compounds from Histone Deacetylase (HDAC) Family
Current Pharmaceutical Design Mechanisms Involved in BACE Upregulation Associated to Stress
Current Alzheimer Research Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Cargo-Delivery Platforms for Targeted Delivery of Inhibitor Cargos Against Botulism
Current Topics in Medicinal Chemistry Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets CDK9 a Potential Target for Drug Development
Medicinal Chemistry Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics